Drug Trial Radar · NCT02451137
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
Last checked: Nov 20, 2026Latest source record: Sep 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,304
Actual
Start
Jun 16, 2015
Primary completion
Mar 2, 2018
Study completion Aug 9, 2018
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (\<8% if age \>=65 years or with defined comorbidities or otherwise \<7%) at 6 months without documented symptomatic (Blood Glucose \<=70 mg/deciliter \[mg/dL\]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting. Secondary Objectives: Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of: * Participant persistence with assigned basal insulin therapy. * Risk of hypoglycemia including the incidence and rate of documented symptomatic and severe hypoglycemia. * Changes in HbA1c, fasting plasma glucose, body weight * Differences in participant and provider- reported outcomes (including Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs) and (DTSQc), Hypoglycemia Patient Questionnaire, and participant and provider reported Global Effectiveness Scale (GES). * Healthcare resource utilization including hospitalizations and emergency department or other provider visits and healthcare costs.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/mlDrug
Pharmaceutical form: solution Route of administration: subcutaneous
Insulin glargine, 100 U/mlDrug
Pharmaceutical form: solution Route of administration: subcutaneous
Insulin detemirDrug
Pharmaceutical form: solution Route of administration: subcutaneous
Background TherapyDrug
Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe HypoglycemiaTime frame: Baseline to Month 6
Locations
427 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number 840731
Birmingham, Alabama
Investigational Site Number 840305
Birmingham, Alabama
Investigational Site Number 840811
Birmingham, Alabama
Investigational Site Number 840218
Gulf Shores, Alabama
Investigational Site Number 840739
Guntersville, Alabama
Investigational Site Number 840367
Huntsville, Alabama
Investigational Site Number 840130
Montgomery, Alabama
Investigational Site Number 840729
Montgomery, Alabama
Investigational Site Number 840281
Saraland, Alabama
Investigational Site Number 840613
Sheffield, Alabama
Investigational Site Number 840634
Sheffield, Alabama
Investigational Site Number 840654
Sheffield, Alabama
Investigational Site Number 840173
Phoenix, Arizona
Investigational Site Number 840555
Phoenix, Arizona
Investigational Site Number 840805
Sun City, Arizona
Investigational Site Number 840725
Conway, Arkansas
Investigational Site Number 840790
Jonesboro, Arkansas
Investigational Site Number 840699
Little Rock, Arkansas
Investigational Site Number 840528
Little Rock, Arkansas
Investigational Site Number 840079
Searcy, Arkansas
Investigational Site Number 840337
Bakersfield, California
Investigational Site Number 840089
El Cajon, California
Investigational Site Number 840024
Escondido, California
Investigational Site Number 840020
Fresno, California
Investigational Site Number 840470
Imperial, California
Investigational Site Number 840155
Inglewood, California
Investigational Site Number 840161
Inglewood, California
Investigational Site Number 840194
Laguna Hills, California
Investigational Site Number 840710
Laguna Hills, California
Investigational Site Number 840204
Lancaster, California
Investigational Site Number 840371
Los Angeles, California
Investigational Site Number 840310
Los Angeles, California
Investigational Site Number 840504
Los Angeles, California
Investigational Site Number 840340
Los Angeles, California
Investigational Site Number 840309
Los Gatos, California
Investigational Site Number 840256
North Hollywood, California
Investigational Site Number 840015
Northridge, California
Investigational Site Number 840056
Norwalk, California
Investigational Site Number 840090
Orange, California
Investigational Site Number 840078
Palm Springs, California
Showing 40 of 427 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.